Fuchs endothelial corneal dystrophy (FECD: MIM136800; Mendelian Inheritance in Man) is a genetically heterogeneous, progressive degenerative disorder of the corneal endothelium with 50% of cases being autosomal dominant and the remaining, sporadic. FECD, broadly classified as early-onset (\<40 years) and late-onset based on the age of presentation, is characterized by a gradual loss of corneal endothelial cells compromising its solute transport function. The hallmarks of FECD are localized thickening of Descemet\'s membrane due to abnormal accumulation of collagenous layer and formation of clinically visible deposits on the surface of the corneal endothelium called "guttae." While *COL8A2* gene mutations have been implicated in early-onset FECD,\[[@ref1]\] mutations in *SLC4A11* and *TCF8* are reported to contribute to a small percentage of late-onset FECD.\[[@ref2][@ref3][@ref4][@ref5]\] Linkage analysis on multigenerational late-onset and small multiplex FECD families have identified many loci; FCD1(13pter-13q21.13), FCD2(18q21.2-q21.32), FCD3(5q33.1-q35.2), and FCD4(9p22.1-9p24.1), apart from other loci on chromosome 1,7,15,17,X.\[[@ref6][@ref7][@ref8]\] Further, genome wide linkage analysis followed by either linkage region targeted next generation sequencing (NGS) or whole exome sequencing (WES) have identified *LOXHD1* and *AGBL1* as candidate genes at FCD2 locus and on chromosome 15, respectively.\[[@ref9][@ref10]\] Single nucleotide polymorphisms (rs17595731, rs9954153, rs613872, and rs2286812) and CTG trinucleotide repeat expansion in the intron of *TCF4* gene are associated with an increased risk for sporadic late-onset FECD and have been significantly replicated in cohorts from different populations.\[[@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\] In this study, the association of these polymorphisms and CTG trinucleotide repeat expansion in the intronic region of *TCF4* gene to late-onset FECD has been comprehensively assessed.

Methods {#sec1-1}
=======

Subjects {#sec2-1}
--------

A cohort consisting of 52 unrelated sporadic late-onset and 5 sporadic early-onset (\<40 years) FECD cases were enrolled in the study. Patients were diagnosed with FECD based on complete ophthalmic examination and/or histopathological evidence following penetrating keratoplasty (PK) or endothelial transplantation.\[[@ref5]\] A total of 148 unrelated age-matched subjects without any ocular abnormalities that were enrolled as part of an epidemiological study previously conducted were used as controls.\[[@ref22][@ref23]\] Ophthalmic examination for the cases and controls included slit lamp, fundus examination, and applanation tension. The cornea was assessed for thickness quantitatively by ultrasound corneal pachymetry (Tomey) and for endothelial morphology qualitatively by specular microscopy (Noncon, ROBO CA). The controls were ruled out for any corneal abnormalities, and clinical findings showed a compact cornea and the absence of "guttae." The cases are a representation of patients across India with different sub-ethnic backgrounds.

Sample collection {#sec2-2}
-----------------

Genomic DNA was extracted from 10 mL whole blood for all cases and controls using NucleoSpin^®^ Blood XL kit (Macherey-Nagel, GmbH, Germany) according to manufacturer\'s instructions. Approval for the study was obtained from the Institutional Review Board and Ethics Committee. The study adhered to the tenets of the Declaration of Helenski and all participants were recruited after written informed consent.

Genotyping of CTG repeats {#sec2-3}
-------------------------

### Quantitative assessment by Sanger DNA sequencing {#sec3-1}

Primers (forward primer: AATGCCAGATGAGTTTGGTG; reverse primer: GCTGCCTGCCTAGGGCTAC) flanking the CTG repeats in the intron of *TCF4* gene were designed using the Primer3 software (v. 0.4.0). Polymerase chain reaction (PCR) amplification was followed by EXO-SAP (*Escherichia coli* exonuclease I and fast alkaline phosphatase, Thermo Scientific, Massachusetts, USA) treatment. Sanger DNA sequencing was performed using Big Dye Terminator v.3.1 Ready Reaction kit (Applied Biosystems, Foster City, USA) in ABIPRISM^®^ 3100-*Avant* Genetic Analyzer (Applied Biosystems, Foster City, USA). The number of repeats was manually counted using the Sequence Analysis v5.1.1 software (Applied Biosystems, Foster City, USA).

### Triplet repeat primed polymerase chain reaction and short tandem repeat assay {#sec3-2}

The short tandem repeat (STR) and Triplet repeat primed PCR (TP-PCR) assays were performed based on protocol followed by Wieben *et al*.\[[@ref14]\] followed by fragment analysis in ABIPRISM^®^ 3100-*Avant* Genetic Analyzer (Applied Biosystems, Foster City, USA). Data analysis was performed using ABI Peak Scanner v1.0 software (Applied Biosystems, Foster City, USA). While STR assay suggests the homo/heterozygosity status of repeats, TP-PCR confirms the nature of homozygous calls in the STR assay, i.e., whether the sample is truly homozygous for the repeats or has an expanded heterozygous repeat which has not been captured.

Genotyping of SNPs rs17595731 and rs9954153 using Taq-Man assay {#sec2-4}
---------------------------------------------------------------

Allelic discrimination by TaqMan assay was performed using Applied Biosystems 7300 - real time PCR system (Applied Biosystems, Foster City, USA) for the SNPs rs17595731 and rs9954153. The PCR protocol was as per the TaqMan^®^ SNP genotyping assays by Applied Biosystems.

Genotyping of SNPs rs613872 and rs2286812 {#sec2-5}
-----------------------------------------

rs613872 and rs2286812 were genotyped using allele specific PCR and PCR-based restriction digestion assays, respectively. Primers were designed using Primer3 software (v. 0.4.0) for both the SNPs.

### Genotyping by restriction enzyme digestion of polymerase chain reaction product {#sec3-3}

PCR followed by digestion with restriction enzyme was performed for rs613872 where the 'T' nucleotide created a restriction site for enzyme ApoI. The presence of 'T' allele cut the 230 bp PCR amplified product into 117 bp and 113 bp fragments.

First, a 20 μL reaction was set up containing 10 mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl~2~ and 0.01% gelatin, 200 μM of dNTP blend (GeneAmpdNTP blend, Applied Biosystems, Foster City, CA, USA), 5 μM of each forward and reverse primer (Sigma-Aldrich, St. Louis, MO, USA) (forward primer-5' CAGGCACTCCCCATTTACTG 3', reverse primer-5' ACCCCAGTAGGGTTGTGATG 3'), 1U of Taq DNA polymerase (GeNei, Bangalore, India), and 100 ng of genomic DNA. A touchdown PCR with annealing temperature of 61.3°C--54.3°C was performed.

Twenty μL restriction digestion reaction was set up with 5 μL of amplified product, 2 μL of NEB buffer 3 (New England BioLabsInc, MA, USA.), 1 μL of 100X BSA, 1U of ApoI enzyme (New England BioLabs Inc., MA, USA). The reaction was incubated at 50°C for 16 h followed by heat inactivation of the enzyme at 80°C for 20 min. The amplified, digested products were analyzed on a 2% agarose gel. To eliminate the possibility of incomplete digestion, overnight restriction digestion protocol was performed, and samples were sequenced at random by Sanger DNA sequencing to confirm the genotype.

### Genotyping by allele specific polymerase chain reaction {#sec3-4}

For SNP rs2286812, two allele specific reverse primers, for the 'C' and 'T' allele were designed additionally, apart from the forward and reverse primers (common forward primer-5'CCAGAGACATTTTGGAAATAACTT 3', common reverse primer-5' CAGTATGCTGGAGAGGGTCA 3', allele specific reverse primer for 'C' allele-5'CAACTCTCAGTCTGTCATCATTAAG 3', allele specific reverse primer for 'T' allele-5'CAACTCTCAGTCTGTCATCATTAAA 3'). Two PCRs were set up, each with the forward, reverse, and the allele specific reverse primers. Twenty μL reactions were set with 10 μM primer (Sigma-Aldrich, St. Louis, MO, USA), 10 mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl~2~, and 0.01% gelatin (GeNei, Bangalore, India), 100 μM of dNTP blend (GeneAmpdNTP blend, Applied Biosystems, Foster City, CA, USA), 1U of Taq DNA polymerase (GeNei, Bangalore, India) and 50 ng of genomic DNA. PCR amplification at annealing temperature of 61.4°C--54.4°C was followed by analysis on a 2% agarose gel.

Statistical analysis {#sec2-6}
--------------------

Two-tailed Fisher\'s exact probability test was performed to study the association of CTG repeat expansion between cases and controls. Association of the SNPsrs17595731, rs9954153, rs613872, and rs2286812 and linkage disequilibrium (LD) between the SNPs to FECD was analyzed using the Haploview v4.2 software.\[[@ref24]\]

Results {#sec1-2}
=======

The 52 late-onset FECD cases included 23 males and 29 females with a mean age of 59.5 ± 10.9. The five early-onset cases were all females. A total of 148 controls were taken for the study with a mean age of 63.8 ± 7.9. The early onset cases in this cohort were previously screened for variations in the *COL8A2* gene. No mutations were reported.\[[@ref25]\] In the cases studied, 58% underwent a PK or Descemet Stripping Endothelial Keratoplasty (DSEK) in at least one eye and 42% had numerous guttae with polymegathism. Among the 42% who did not undergo corneal transplant, 9% of the cases showed corneal decompensation with corneal edema.

Assessment of CTG trinucleotide repeats in cases and controls {#sec2-7}
-------------------------------------------------------------

The CTG repeats were assessed quantitatively by manually counting the sequence electrophoretogram and qualitatively by TP-PCR and STR assays. We found 9/52 (17.3%) cases with repeat expansions \>50 repeats when compared to 4/125 (3.2%) controls. Of the 9 cases with repeat expansions, 2 cases showed homozygous expansions \>50 repeats in both alleles while the remaining 7 cases were heterozygous for the repeat expansion with \>50 repeats in one allele. By Sanger DNA sequencing, we were able to count up to 75 repeats. The expansions in alleles were confirmed by TP-PCR assay. A significant association of expanded trinucleotide repeats to late-onset FECD was observed (*P* = 2.4 × 10^−3^). The odds of risk for late-onset FECD was found to be 6.3 times higher (odds ratio \[OR\] 6.3, 95% confidence interval \[CI\]: 1.8, 21.6), given the presence of expanded CTG trinucleotide repeats (\>50 repeats) to baseline CTG repeats (\<50 repeats) and was statistically significant. Association including the five early-onset cases was also done, and although we found a heterozygous expansion in one early-onset case, there was no notable change in *P* value \[[Table 1](#T1){ref-type="table"}\].

###### 

CTG repeat expansion in late onset cohort alone (*n*=52) and with early onset cases (*n*=57)

![](IJO-65-931-g001)

Association of rs613872 and rs17595731 to late-onset Fuchs endothelial corneal dystrophy {#sec2-8}
----------------------------------------------------------------------------------------

Of the four SNPs (rs17595731, rs9954153, rs613872, and rs2286812), rs613872 (*P* = 4.57 × 10^−5^, OR 3.6, 95% CI: 1.7, 7.3), and rs17595731 (*P* = 1.87 × 10^−5^, OR 15.3, 95% CI: 3.1, 73.4) showed a significant association to late-onset FECD. Although the minor allele frequency of SNP rs17595731 was 0.028, reports on the inclusion of SNPs with minor allele frequency \>0.01 and the proven association of rs17595731 to late-onset FECD indicate an association of the SNP to the disease.\[[@ref26][@ref27][@ref28]\] The *P* value for rs2286812 indicated significance; however, the Hardy--Weinberg Equilibrium was considerably deviated. SNP rs9954153 did not show any association. There was no substantial change in the *P* value of the 4 SNPs with the inclusion of 5 early-onset cases in the study \[Tables [2](#T2){ref-type="table"}--[5](#T5){ref-type="table"}\]. The four SNPs are not in LD.

###### 

Genotype data of SNP rs9954153 for late-onset cohort alone (*n*=52) and with early-onset cases (*n*=57)
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###### 

Genotype data of SNP rs2286812 for late-onset cohort alone (*n*=52) and with early-onset cases (*n*=57)
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###### 

Genotype data of SNP rs613872 for late-onset cohort alone (*n*=52) and with early-onset cases (*n*=57)

![](IJO-65-931-g004)

###### 

Genotype data of SNP rs17595731 for late onset cohort alone (*n*=52) and with early onset cases (*n*=57)
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Discussion {#sec1-3}
==========

Late-onset FECD is a complex disease involving genetic and environmental factors. A vast proportion of PK has been indicated by FECD in North America (28%) and Europe (20.6%).\[[@ref29]\] In the Indian population, a study has shown that about 5.3% of PK cases came to clinic with FECD as the cause.\[[@ref30]\]

Apart from the identification of various candidate genes contributing to FECD, association studies gained importance when Baratz *et al*. identified genetic risk variants by Genome-wide association studies for the first time in 2010. Four SNPs in the intron of *TCF4* were found to be independently associated with FECD.\[[@ref31]\] Further, replication studies on these risk variants in various populations identified a significant association of rs613872.\[[@ref19][@ref20]\] This SNP was studied in two Indian cohorts and association was reported in only one of the two studies which involved 82 sporadic late-onset FECD cases.\[[@ref16][@ref32]\] We have genotyped these four risk variants and observed that the 'G' allele of rs613872, and additionally, the 'C' allele of rs17595731 was associated with sporadic late-onset FECD cases in our cohort. Our data adds value to the significance of association of this SNP to late-onset FECD and for the first time shows an association of rs17595731 to FECD in this Indian cohort.

Breschel *et al*. reported novel polymorphic unstable trinucleotide repeats (CTG) in the intron of *TCF4* gene in the population while scanning chromosome 18 specific library in a study on bipolar disorder. However, the CTG repeat expansions did not show association to the disorder.\[[@ref33]\] As intronic region of *TCF4* gene is a hotspot for SNPs associated with late-onset FECD, Wieben *et al*. studied the significance of these repeats and reported an association of \>50 expanded CTG repeats to late-onset FECD\[[@ref14]\] and the same has been replicated across different ethnicities.\[[@ref12][@ref13][@ref15][@ref16][@ref17][@ref18]\] Some studies have considered \>40 repeats as criteria for expansion and have found a significant association to the disease.\[[@ref13][@ref15][@ref18]\] Our study confirmed a strong association of \>50 repeat expansions with late-onset FECD. We did not observe intermediate repeat expansions between 40 and 50 repeats in our cohort. However, compared to the seven other studies on various ethnicities including that of another Indian cohort, we observed a lower percentage of cases with expanded CTG repeats \[[Table 6](#T6){ref-type="table"}\].

###### 

Comparison of expanded CTG repeats in cases and controls across ethnicities based on literature
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*TCF4* gene coding for the E2-2 protein is expressed in the corneal endothelium and plays a vital role in the regulation of cell adhesion protein, E-cadherin and is thus hypothesized to promote endothelial-mesenchymal transition (EMT) by increased expression of *ZEB1*. When there is a loss of corneal endothelial cells, the stem cells from the limbus, migrate to the site of loss or damage and replenish the endothelial cells by the mechanism of EMT. The exact sequence of events in FECD remain unknown, and it is speculated that the dysregulation of E2-2 expression leading to reduced *ZEB1* expression may affect migration of progenitor cells to replenish the lost or damaged endothelial cells. Due to loss of cells, subsequent degeneration and progressive vision impairment could occur.\[[@ref34]\]

Du *et al*. observed RNA foci in the corneal endothelial cells of late-onset FECD patients with CTG repeat expansions. When compared with RNA foci in myotonic dystrophy (DM1), the foci were similar in morphology. RNA Seq data revealed differential splicing of five genes including *MBNL1* in the corneal endothelium of FECD patients which was also observed in DM1. Splicing of *MBNL1* is implicated in EMT thus providing evidence for a possible role in FECD pathogenesis.\[[@ref35]\] Further characterization studies may provide insight into the mechanisms involved in the pathogenesis of FECD due to repeat expansion and its relevance to EMT.

Conclusion {#sec1-4}
==========

SNP rs613872 and CTG repeat expansions have consistently shown association to late-onset FECD across populations of various ethnicities. As the age of onset and progression of the disease was highly variable in this cohort, no genotype-phenotype correlation was done. Genotyping of the associated SNPs in sporadic cases of late-onset FECD may be useful in counseling the patient for regular follow-up and timely clinical management, and the same may be offered to the at risk family members such as siblings and offspring. A larger sample size with a higher representation of different sub-ethnic groups of the Indian population will strengthen our finding. This is the first study to report a significant association of rs17595731 to late-onset FECD in the Indian population.
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